ArticleScientific reports2025
Correlation analysis of serum neurofilament light chain and glial fibrillary acidic protein levels with amyotrophic lateral sclerosis.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- The Molecular Basis of Partial Reversal or Significant Slowing of ALS, Parkinson's Disease, and Lewy Body Dementia by Mesenchymal Exosomes/Secretome.International journal of molecular sciences · 2026Article
- Precision Channel Engineering of Nanotube-Embedded Organic Electrochemical Transistors for Ultrasensitive Neurofilament Light Chain Detection.ACS applied bio materials · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Neurofilament light chain (NFL) and glial fibrillary acidic protein (GFAP) are considered to be a promising biomarker for the diagnosis of amyotrophic lateral sclerosis (ALS) and assessment of disease progression. To investigate the correlation between serum neurofilament light chain protein (NFL) and glial fibrillary acidic protein (GFAP) levels and amyotrophic lateral sclerosis (ALS). Serum NFL and GFAP levels were measured in 12 ALS patients and 12 healthy controls (HC) using the Single-molecule array (Simoa) technique. Serum NFL and GFAP levels in ALS patients were 81.49 ± 47.06 pg/mL and 104.42 ± 37.31 pg/mL, respectively, significantly higher than those in healthy controls (9.21 ± 3.05 pg/mL and 57.71 ± 11.64 pg/mL; P < 0.001). Serum NFL and GFAP levels in ALS patients were correlated with the duration of the disease as respectively (r = 0.746, P = 0.005; r = 0.668, P = 0.018). In this study, we investigated the diagnostic value of serum NFL and GFAP levels in the ALS population and their clinical significance using the Simoa technique. The results showed that serum NFL and GFAP levels may be potential biomarkers for ALS diagnosis, and is positively correlated with disease progression. However, its diagnostic specificity awaits further studies that include disease controls.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.